Ray, Samiran http://orcid.org/0000-0002-3738-4672
Heslegrave, Amanda
Jones, Gareth
Feinstein, Yael
Wray, Jo
Zetterberg, Henrik
Peters, Mark J.
Ramnarayan, Padmanabhan
Funding for this research was provided by:
Great Ormond Street Hospital Charity
UK Paediatric Critical Care Society
Article History
Received: 28 January 2023
Accepted: 1 November 2023
First Online: 21 November 2023
Declarations
:
: Ethical approval for BASIC was granted by the East Midlands—Nottingham NRES Committee (ref 13-EM-0399). Informed consent was gained for BASIC study participation from families, with an option to withdraw consent at any stage of the study.
: Informed consent was gained for BASIC study participation from families, with an option to withdraw consent at any stage of the study.
: SR has undertaken consultancy work with Roche. HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, Annexon, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Pinteon Therapeutics, Red Abbey Labs, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics and Wave; has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen and Roche; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). No other authors have declared conflicts of interest.